Improving the effectiveness of a new drug for treating filarial infections.
Official title: Heteromers and L-type calcium channels: Increasing the potency of emodepside in filarial nematode model, Brugia malayi
Funded at Creighton University · NIH-11057243 · Data updated 2026-11-12
This study is looking at how to make a promising drug called emodepside even better for treating infections caused by a type of worm that leads to lymphatic filariasis, a condition that affects many people around the world.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creighton University NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | November 15, 2024 |
| Project end | October 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $226,738 |
| NIH project number | 1R21AI180688-01A1 |
| Project ID | NIH-11057243 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from lymphatic filariasis or related filarial infections.
✕Less likely to help
Patients who do not have filarial infections or those who are not affected by lymphatic filariasis may not benefit from this research.
What this research studies
This research focuses on enhancing the potency of emodepside, a promising drug for treating filarial nematode infections, particularly Brugia malayi. The study aims to understand how emodepside interacts with specific calcium channels in nematodes, which could lead to more effective treatments. By using a model organism, C. elegans, researchers will investigate the drug's pharmacological effects and how it can be optimized for better efficacy against adult filarial parasites. This could potentially lead to significant advancements in the treatment of lymphatic filariasis, which affects millions worldwide.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for filarial infections, improving health outcomes for affected individuals.
How similar studies have gone: Other research has shown promise in enhancing drug efficacy for similar parasitic infections, indicating potential for success in this approach.
Where this research is happening
-
Creighton University
Omaha, United States Active
Researchers
- Principal investigator: Kashyap, Sudhanva Srinivas — Creighton University
- Study coordinator: Kashyap, Sudhanva Srinivas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.